



# INDOLE AS A THIOREDOXIN INHIBITOR FOR ANTICANCER ACTIVITY

Sushama Kailas Pawal<sup>1</sup>, Shailaja B. Jadhav<sup>2</sup>

Progressive Education Society Modern College of Pharmacy Nigadi, Pune.

**Abstract:** Malignant growth, a significant general medical condition, shows huge redox modification. Thioredoxin (Trx) framework, including Trx and Trx reductase (TrxR), as well as Trx-collaborating protein (TXNIP) play significant parts in controlling the cell redox balance in malignancy cells. Indoles are regular items notable for their anticancer action, which is identified with their capacity to induce cell passing for some malignancy cell lines. This audit addresses indoles as regular items, system of indoles, encouraged acceptance and ongoing examinations with indoles and related mixtures that were explored by means of anticancer screening and that prompted drug endorsement. Thioredoxin (Trx), thioredoxin reductase (TrxR), and NADPH are key individuals from the Trx framework that is engaged with redox guideline and cell reinforcement protection. Numerous tumor cells express significant degrees of Trx and TrxR, which can be liable for drug obstruction in tumorigenesis. Hindrance of the Trx framework may in this manner add to malignant growth treatment and improving chemotherapeutic specialists. There are currently various effective normal and manufactured inhibitors with chemotherapy applications having antitumor movement going from oxidative pressure enlistment to apoptosis. In this article, we first depicted the highlights and elements of the Trx framework and afterward surveyed briefly its relationships with malignancy. At last, we summed up the current information about the Trx/TrxR inhibitors as anticancer medications.

**Keywords:** Indoles, Thioredoxin, Thioredoxin reductase, Cancer, Cancer therapy, Oxidative stress.

## Introduction

An indole is a sweet-smelling heterocyclic composite which has its heterobicyclic arrangement as a six-membered ring melded to a five-membered pyrrole ring. 'Indole' is the name given to all indole derivatives which have an indole ring framework. Indoles [1,2] are acquired from coal pitch or an assortment of plants and created by the bacterial rot of tryptophan in the intestine. It has been incorporated by one of the most seasoned techniques that known as Fischer indole amalgamation. Indoles [2] work as sign particles in plants and creatures. They additionally fill in as a crude material, core building blocks and a productive bunch of various basic biochemical particles and mixtures, like alkaloids, indigoids, and so forth. The majority of these significant atoms and mixtures start, either completely or somewhat, from bio-oxidation of indoles. Numerous scientific agents have revealed that oxidative pressure is a typical component of numerous malignancies, also, the thioredoxin (Trx) cancer prevention agent framework, as a key factor firmly connected to the pathogenesis of a few human infections, is over-communicated in different tumors [4–9]. The Trx framework is a fundamental redox control framework that is fundamental to searching ROS and shielding cells from the harms of free revolutionaries [1, 5]. This framework contains a Trx protein as a benefactor of hydrogen that is decreased by Trx reductase (TrxR) compound utilizing NADPH to advance its exercises [10]. It is grounded that the Trx framework is associated with cytoprotective cycles, despite the fact that few specialists have noticed its tumor-advancing highlights [5, 10–13].

On the side of this view, various creators have detailed the relationship between's the over-articulation of the Trx framework and various signs of disease, for example malignant growth cell drug opposition [11–13]. Thinking about these discoveries, focusing on Trx/TrxR has been perceived as a promising methodology for malignancy treatment just as sharpening tumor cells to chemotherapeutic medications [14, 15]. In the current article, we sum up the Trx framework capacities and its relationship with tumor science, and afterward we endeavor to give an outline of the current information on Trx/TrxR inhibitors.

## The thioredoxin system in cancer

It is notable that the Trx framework has various capacities in ordinary physiological conditions, particularly in cancer prevention agent safeguard in shielding cells from malignant growth, despite the fact that various articles have revealed that the Trx framework is included in tumor science at various levels [4, 5, 9, 10]. This can be pertinent to the state of tumor cells which are under oxidative pressure portrayed by the overproduction of cancer prevention agent proteins [5, 7, 8]. In such manner, a few specialists have shown that Trx articulation is expanded in various kinds of malignancies, for example, colorectal [9], lung [4], pancreatic [8] and gastric diseases [7]. The overexpression of Trx proteins has been appeared to associate with the upgrade of malignancy cell development, which happens either through direct development guideline or because of apoptosis hindrance. In line with this, it has been exhibited that the cDNA cloning of Adult T cell leukemia-determined factor (ADF) shows incredible homology with Trx and ADF/Trx can advance caged cell development, just like the case with lymphocytes [9, 10]. As of late, an in vivo study demonstrated that

subcutaneous infusions of two human lung carcinoma cell lines with high and low articulation of Trx protein into extreme joined immunodeficient (SCID) mice, show the development of wide furthermore, little subcutaneous tumors that are reliant on the level of Trx articulation in the infused cells [21]. Another examination tracked down that wild-type Trx transfected MCF-7 bosom malignant growth cells show a few times expansion in cell multiplication and state arrangement in delicate agarose contrasted with redox-inert freak Trx transfected cells [22]. So far this area has shown that Trx has development advancing impacts and its overexpression isn't only a wonder related with tumor movement. It is currently important to clarify momentarily the against apoptotic elements of Trx framework.

### **The Trx system as a therapeutic target in cancer**

The Trx framework is viewed as an expected anticancer objective furthermore, the focal point of some chemotherapeutic reagents [83–89]. The purposes behind picking the Trx framework as an objective of anticancer medications are the indispensable part of this framework in apoptosis guideline and the overexpression of its individuals in numerous malignancy cells [14]. Hindrance of the Trx framework can modify intracellular redox state and initiate apoptosis through ROS aggregation, ASK1 actuation, and restraint of procaspase-3 nitrosylation [14, 18, 11]. By thinking about the developing interest in focusing on the Trx framework, we will examine a few Trx framework inhibitors in the last piece of the current paper.

### **Trx inhibitors**

#### **1-Methyl-propyl-2-imidazolyl disulfide (PX-12)**

1-Methyl-propyl-2-imidazolyl disulfide (IV-2) (likewise known as PX-12) is a little particle inhibitor of Trx protein that was found initially utilizing a cell line-coordinated screening approach (CDSA) [23]. The methodology was utilized to screen disulfide compounds because of their development inhibitory impacts on disease cell lines in vitro. The inhibitory system of PX-12 gives off an impression of being through restricting to the Cys73 buildup of cytosolic Trx1, in this manner delivering it latent irreversibly also, incapable to go about as TrxR1 substrate. In an examination into PX-12, Tan et al. (2014) featured proof that this compelling Trx1 inhibitor could instigate apoptosis in intense myeloid leukemia (AML) cells and increment the declaration of initiated caspase-3 of every a portion subordinate way [91]. In 2006, Baker et al. distributed a paper where they analyzed the impacts of PX-12 therapy on plasma convergence of Trx1 and VEGF in disease patients with high mean plasma levels of them during a stage I study [24]. Their investigations showed that PX-12 treatment can decrease the convergence of the two proteins in plasma [13]. Until this point in time, it has been uncovered that the articulation of VEGF protein as a vital factor for angiogenesis is managed by HIF-1 record factor which is one of the downstream focuses of Trx protein [15]. This view is upheld by ongoing perceptions of Welsh (2003) who have shown that PX-12 reductions the degrees of HIF-1 $\alpha$  and thusly VEGF protein in refined malignant growth cells and human tumor xenografts

by Trx1 restraint. PX-12 is the first Trx1 protein modulator that has been progressed into clinical preliminaries for malignant growth treatment [16]. This medication has finished a stage I preliminary and now is in stage II for the therapy of pancreatic malignancy [17]. Notwithstanding immediate restraint of Trx protein, there is an elective methodology that can prompt Trx restraint through quality articulation guideline of an endogenous inhibitor. Suberoylanilide hydroxamic corrosive (SAHA) is a malignant growth helpful specialist which targets Trx protein by implication.

## **2-Suberoylanilide hydroxamic acid (SAHA)**

Histone deacetylase inhibitors (HDACis) are novel disease remedial medications that have a place with the wide class of chromatin-altering specialists (CMAs). These synthetic mixtures have tumor-specific cytotoxic action and hinder deacetylation of lysine deposits in histones [98]. Hindrance of histone deacetylation actuates derepression of quality articulation and is related with the avoidance of chromatin buildup. The guideline of quality articulation is reliant on histone acetylation and deacetylation that intercede the connection between histone edifices and chromatin [19]. HDACis comprise of various mixtures which are arranged dependent on their synthetic moieties that have the job of restricting to the zinc-containing reactant area of HDAC compounds [101]. SAHA is a half breed polar compound (HPC) that has a place with the hydroxamate gathering of HDACis [20]. In 2006, this epigenetic altering drug was the first FDA-affirmed HDACis that entered the clinical oncology market for the treatment of cutaneous T-cell lymphoma (CTCL) [13]. Presently the adequacy of SAHA is tried in clinical preliminaries for the treatment of different malignancies [14]. This antitumor compound demonstrations by restricting to the reactant site of HDAC proteins (class I and II), causing the restraint of their catalyst movement and accordingly the amassing of acetylated histones [15]. SAHA has been accounted for to instigate development capture in a wide scope of changed cells in tumorbearing creatures and in vitro at focuses that don't influence the development of typical cells [102, 106, 107]. In 2002, Butler et al. utilized microarray investigation to recognize quality articulation profiles in prostate malignancy cell lines that were treated with SAHA [3]. They showed SAHA could increment the quality articulation of the endogenous Trx inhibitor, TBP-2, as other disease cell types [83]. The upregulation of TBP-2 that was actuated by SAHA's hindrance of HDACs could inactivate the elements of Trx by restricting to it and consequently lead to oxidative pressure condition [2]. In expansion to TBP-2, the overexpression of ASK-1 is another outcome of SAHA treatment that prompts the enactment of the apoptotic pathway [1]. The focusing of the Trx framework by SAHA has all the earmarks of being intriguing because of its backhanded Trx hindrance and tumor-particular cytotoxic action.



## TrxR inhibitors

### 1. Gold-containing compounds

Gold salts are exceptionally proficient ionic substance compounds of gold that are utilized clinically to smother various perspectives of the provocative interaction and to forestall the movement of persistent infections like rheumatoid joint pain (RA) what's more, human tuberculosis [4]. As of late, these mixtures have likewise been demonstrated to be drug up-and-comers in malignant growth chemotherapy because of their cytotoxic impacts on various cell types. The proposed system of their anticancer impacts is by all accounts dependent on their connection with DNA or other cell targets, for example, protein. It is realized that gold has a high proclivity for thiol gatherings furthermore, can focus on the diminished type of TrxR [5]. This is likewise upheld by an in vitro study, where helpful gold mixtures are demonstrated to effectsly affect the decreased type of TrxR in the nanomolar range [115]. S-triethylphosphinegold (I)- 2,3,4,6-tetra-O-acetyl-1-thio- $\beta$ -D-glucopyranoside (Auranofin) is a gold (I)- containing compound that was endorsed as an antiarthritic drug initially also, has been produced for the therapy of malignancy [6].

Auranofin could advance its cytotoxic impacts in human ovarian disease cells that they are impervious to cisplatin and show a higher action of TrxR [6]. In detached purged mitochondria, it is proposed that auranofin treatment could lead to mitochondrial glitch and arrival of proapoptotic factors, similar to cytochrome c [7]. It has been appeared that auranofin is competent to actuate the amassing of mitochondrial H<sub>2</sub>O<sub>2</sub> through the TrxR restraint that diminishes the rate by which the least difficult peroxide is eliminated [88]. Recently, [Au(d<sup>2</sup>-pypp)<sub>2</sub>]Cl that is an intriguing gold (I) phosphine complex prompted headway in anticancer treatment due to its capacity to focus on the mitochondria notwithstanding the Trx framework (both Trx and TrxR) [9]. The aftereffects of an in vitro study demonstrated that [Au(d<sup>2</sup>-pypp)<sub>2</sub>]Cl could incite the mitochondria-interceded apoptosis through initiation of caspases 3 and 9 in bosom malignancy cells [9]. Other than the expanded mitochondrial film capability of tumor cells, the lipophilic cationic property of this gold (I) phosphine complex is another fundamental factor for its amassing in mitochondria [9].

### 2. Arsenic trioxide (ATO or As<sub>2</sub>O<sub>3</sub>)

ATO is known as a moderately protected and adequate treatment for intense promyelocytic leukemia (APL) patients who have backslid or recently analyzed [21, 22]. In September 2000, this arsenic-containing compound was endorsed by FDA for the enlistment and solidification treatment of APL patients [23]. ATO has been thought to intervene its natural impacts by cooperations with available cysteine buildups on cell proteins [24]. An in vitro study led by Lu et al. appeared that ATO could restrain the diminished type of mammalian TrxR irreversibly by focusing on its sulfhydryl bunches with an IC<sub>50</sub> of 0.25  $\mu$ M [6]. It has likewise been recommended that ATO could add to the enlistment of apoptosis and hindrance of multiplication through various pathways [9]. The development inhibitory impacts of ATO were controlled by an examination of human bosom malignant growth cells. Results have shown that ATO treatment instigates extreme Trx oxidation furthermore, represses the development of cells following 2 days [8].

### 3. Nitroaromatic compounds (DNCB)

1-Chloro-2,4-dinitrobenzene (DNCB) is a nitroaromatic compound which is utilized in preliminaries as a sharpening specialist for chemotherapy of melanoma patients [6]. It has been shown that DNCB could restrain TrxR irreversibly through dinitrophenyl-alkylation of both the cysteine and its neighboring selenocysteine in the carboxy-terminal theme of the catalyst [7]. The alkylation of TrxR catalyst by DNCB incites the loss of a Se- dinitrophenol bunch from the adjusted protein furthermore, accordingly prompts the dehydroalanine development at the previous selenocysteine position [8]. DNCB is moreover competent to build the age of superoxide by enlistment a high NADPH oxidase movement of the altered protein [10]. Its system for this action includes the decreased

Craze in the changed catalyst that can catalyze the exchange of one electron to a nitro gathering of the dinitrophenyl moieties of the dinitrophenyl-alkylated catalyst (dnp-TrxR). The electron move prompts the arrangement of nitro anion extremist that sequentially responds with oxygen to yield superoxide anion. It appears to be that immunostimulation impacts of this little electrophilic compound are intervened by expanded extracellular degree of oxidized Trx and enlistment of oxidative pressure [13].

### 4. Platinum compounds

Cisplatin [cis-diamminedichloridoplatinum (II)] is a platinum compound that was affirmed by the FDA in 1978 for use in the therapy of disease [13]. This DNA-harming compound represses TrxR in a portion and time-subordinate way by focusing on the profoundly receptive and very well-open selenocysteine buildup on the adaptable C-terminal arm of TrxR. It has additionally been shown that the hindrance of TrxR by cisplatin is incredibly explicit and irreversible. The platinum compound oxaliplatin as a simple of cisplatin additionally effectsly affects TrxR and can show similar degree of its restraint [14].

### 5. Polyphenolic compounds

Data from several sources have recently identified the role of naturally occurring compounds, like polyphenols (curcumin and some flavonoids) as potential antitumor agents. Curcumin (diferuloylmethane) is a widely consumed phytochemical compound, has been shown to inhibit TrxR irreversibly in a dose- and time-dependent manner. Curcumin modification of cysteine 496 and selenocysteine 497 in the C-terminal TrxR redox-active site was confirmed to be its inhibitory mechanism [18]. Alkylation of TrxR enzyme by curcumin leads to increased oxidative stress through acquired NADPH oxidase activity. Expansion of curcumin to refined human cervical HeLa disease cells additionally prompted TrxR hindrance with an IC<sub>50</sub> of 15 μM. Flavonoids are a significant group of plant furthermore, contagious auxiliary metabolites that have variety in their synthetic designs. In a past report on 3-hydroxyl-containing flavonoids, as quercetin and myricetin, it was shown that these dynamic mixtures additionally apply their TrxR inhibitory impacts by a comparable system of activity. The TrxR restraint by these mixtures was found to be subject to the grouping

of flavonoids, time, also, NADPH. The examination of adenocarcinomic human alveolar basal epithelial A549 cell lysate that was dealt with myricetin  $> 50 \mu\text{M}$  showed a TrxR movement decrease corresponded with Trx protein oxidization [17].

## Conclusion

It is generally acknowledged that the Trx framework as an amazingly significant piece of thiol controlling frameworks, is effectively included in redox homeostasis and upkeep of cell endurance in typical cells. What's more, its overexpression has been appeared in an assortment of malignancy cells and assumes vital parts in tumor improvement and keeping up tumor aggregates. It is moreover presently evident that the Trx framework is a significant objective for malignant growth treatment and chemoprevention preliminaries. In this examination, we intended to depict a portion of the mixtures that explicitly restrain Trx framework individuals. Trx framework, further examinations are additionally needed to improve the adequacy and the generally speaking antitumor treatment reaction. Besides, more explores ought to be performed for improving particularity and selectivity of Trx framework inhibitors toward malignant growth cells and decreasing their results.

## References

1. Fariba Mohammadi<sup>1,2</sup> · Arash Soltani<sup>1,2</sup> · Atefeh Ghahremanloo<sup>1</sup> · Hossein Javid<sup>1</sup> · Seyed Isaac Hashemy<sup>1,3</sup> The thioredoxin system and cancer therapy: a review Received: 5 June 2019 / Accepted: 25 July 2019
2. Mahaveer Prasad Purohit, Neeraj Kumar Verma, Aditya Kumar Kar, Amrita Singh, Debabrata Ghosh, and Satyakam Patnaik Inhibition of Thioredoxin Reductase by Targeted Selenopolymeric Nanocarriers Synergizes the Therapeutic Efficacy of Doxorubicin in MCF7 Human Breast Cancer Cells Publication Date (Web): 25 Sep 2017
3. Junmin Zhang , Xinming Li , Xiao Han , Ruijuan Liu , Jianguo Fang Targeting the Thioredoxin System for Cancer Therapy September 2017, Pages 794-808
4. Jin-Jing Jia, Wen-Shuo Geng, Zhan-Qi Wang, Lei Chen & Xian-Si Zeng Cancer Chemotherapy and Pharmacology 84, 453– 470(2019) The role of thioredoxin system in cancer: strategy for cancer therapy Published: 11 May 2019
5. Fulvio Saccoccia, Francesco Angelucci, Giovanna Boumis, Daniela Carotti, Gianni Desiato, Adriana E Miele, and Andrea Bellelli, Thioredoxin Reductase and its Inhibitors Published online 2014 Sep.
6. Baoxin Zhang, Junmin Zhang, Shoujiao Peng, Ruijuan Liu, Xinming Li, Yanan Hou, Xiao Han & Jianguo Fang Thioredoxin reductase inhibitors: a patent review : Taylor & Francis Journal: Expert Opinion on Therapeutic Patents

7. Harshita Sachdeva 1 \* Jaya Mathur1 Anjali Guleria1 INDOLE DERIVATIVES AS POTENTIAL ANTICANCER AGENTS: A REVIEW 1Department of Chemistry, University of Rajasthan, Jaipur-302004, Rajasthan, India. J. Chil. Chem. Soc. vol.65 no.3 Concepción set. 2020
8. Mardia Telep El Sayed National Research Center, Egypt Nehal Hamdy National Research Center, Egypt Dalia Osman National Research Center, Egypt Khadiga M. Ahm National Research Center, Egypt. Indoles as anticancer agents October 2015, Received: 30 July 2015; : 4 th September 2015; Published Online: 6 th October 2015.
9. J. H. Skerritt, and G. A. Johnston, Eur J Pharmacol 89, 193, (1983)
10. R. Elliott, Mayo Clin Proc 76, 511, (2001).
11. P. I. Joyce, D. Rizzi, G. Calo, D. J. Rowbotham and D. G. Lambert, Anesth Analg 95, 1339, (2002).
12. E. Mutschler and H. Derendorf, Med. Pharm Scientific Publishers, Stuttgart, 16, (1995).
13. Guyton and Hall, "Text book of Medical Physiology" Elsevier-Saunders, 7th Ed (2005). [ Links ]
14. L. P. Garrod, Br. Med. J., 1 (5172), 527, (1960).
15. C. H. Dash, Penicillin allergy and the cephalosporins. J Antimicrob Chemother, 1, 107, (1975).
16. E. Goldstein, Am J Med 82, 3, (1987).
17. W. Kingston, J History Med Allied Sci 59, 441 (2004).
18. S. Senapati, A. K. Mahanta, S. Kumar, P. Maiti, Signal transduction and targeted therapy, 3, 1, (2018).
19. V. Mistiaen, Time and the great healer. The history behind the discovery of streptomycin (2002).
20. P. Martins, J. Jesus, S. Santos, L. R. Raposo, C Roma-Rodrigues, P. V. Baptista, A. R. Molecules 20,16852, (2015).
21. S. Kakkar, S. Kumar, B. Narasimhan, S. M. Lim, K. Ramasamy, V. Mani, S. A. Shah, Chemistry Central Journal 12, 96, (2018).
22. A. Kumari, R. K. Singh, Bioorganic chemistry 103021, (2019).
23. S. J. Singh, R. Singla, V. Jaitak, Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents) 16, 160, (2016).
24. M. Z. Zhang, Q. Chen, G. F. Yang, European journal of medicinal chemistry 89, 421, (2015).